ABBV-181: Clinical Trials

18 trials of ABBV-181, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

7 completed, 6 terminated, 4 active not recruiting, 1 recruiting. 18 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	18	Completed 7, Terminated 6, Active not recruiting 4, Recruiting 1
Phase 2	1	Recruiting 1

Follow ABBV-181: new trials by email Literature Review of ABBV-181 trials Research Report on ABBV-181

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab - Non Small Cell Lung Carcinoma, c-MET	Phase 1 / Phase 2	Recruiting	AbbVie	252	2025-03-06	2026-10-27
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab - Hepatocellular Carcinoma (HCC)	Phase 1	Terminated	AbbVie	3	2024-09-11	2026-10-21
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors ABBV-303, Budigalimab - Solid Tumors	Phase 1	Terminated	AbbVie	27	2024-02-06	2025-10-27
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors ABBV-706, Cisplatin, Budigalimab - Advanced Solid Tumors	Phase 1	Active not recruiting	AbbVie	288	2022-12-05	2026-05-07
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis ABBV-927, Budiglimab, modified FOLFIRINOX - Pancreatic Cancer	Phase 1	Terminated	AbbVie	40	2021-05-28	2025-01-07
Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV) Budigalimab, Placebo - Human Immunodeficiency Virus (HIV)	Phase 1	Completed	AbbVie	33	2021-03-15	2022-10-17
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 ABBV-181, Placebo - Human Immunodeficiency Virus (HIV), HIV Infection	Phase 1	Completed	AbbVie	41	2020-01-30	2023-03-09
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma ABBV-181, ABBV-368, ABBV-927 - Head and Neck Cancer	Phase 1	Terminated	AbbVie	3	2020-01-22	2020-12-31
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer	Phase 1	Completed	AbbVie	30	2020-01-22	2023-02-27
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors ABBV-927, ABBV-368, ABBV-181 - Cancer, Advanced Solid Tumors	Phase 1	Active not recruiting	AbbVie	150	2019-05-21	2026-09-02
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors Livmoniplimab, Budigalimab - Advanced Solid Tumors Cancer	Phase 1	Active not recruiting	AbbVie	364	2019-02-21	2025-05-25
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer ABBV-011, Budigalimab - Small Cell Lung Cancer	Phase 1	Completed	AbbVie	132	2018-10-24	2024-02-09
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers SC-004, ABBV-181 - Cancer	Phase 1	Terminated	AbbVie	24	2017-06-14	2019-05-14
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors ABBV-368, ABBV-181 - Advanced Solid Tumors Cancer	Phase 1	Completed	AbbVie	139	2017-03-21	2022-04-28
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer SC-006, ABBV-181 - Colorectal Cancer	Phase 1	Terminated	AbbVie	29	2017-03-08	2020-02-20
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors ABBV-927, ABBV-181 - Advanced Solid Tumors Cancer	Phase 1	Active not recruiting	AbbVie	163	2017-02-22	2026-01-09
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Venetoclax, Rovalpituzumab Tesirine, ABBV-181 - Advanced Solid Tumors	Phase 1	Completed	AbbVie	182	2016-12-14	2022-04-14
A Study of ABT-165 in Subjects With Solid Tumors paclitaxel, FOLFIRI, ABT-165 - Advanced Solid Tumors	Phase 1	Completed	AbbVie	101	2013-08-08	2023-12-15

Conditions studied

Sponsors

Countries

Results publications

NIH funding